预约演示
更新于：2026-02-27
Hydrochlorothiazide/Olmesartan Medoxomil
奥美沙坦酯氢氯噻嗪
更新于：2026-02-27
概要
基本信息
药物类型 小分子化药 |
别名 Benicar HCT、Olmesartan Medoxomil and Hydrochlorothiazide、Olmesartan medoxomil/hydrochlorothiazide + [6] |
作用方式 拮抗剂、抑制剂 |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)、NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂) |
治疗领域 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批日期 英国 (2003-03-30), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C36H38ClN9O10S2 |
InChIKeyCJPRWUSPLWISJM-UHFFFAOYSA-N |
CAS号760190-74-7 |
关联
28
项与 奥美沙坦酯氢氯噻嗪 相关的临床试验CTR20221126
评估受试制剂奥美沙坦酯氢氯噻嗪片（规格：20 mg/12.5 mg）与参比制剂奥美沙坦酯氢氯噻嗪片（复傲坦®）（规格：20 mg/12.5 mg）在健康成年受试者餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究
CTR20221127
评估受试制剂奥美沙坦酯氢氯噻嗪片（规格：20 mg/12.5 mg）与参比制剂奥美沙坦酯氢氯噻嗪片（复傲坦®）（规格：20 mg/12.5 mg）在健康成年受试者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究
CTR20213015
奥美沙坦酯氢氯噻嗪片在健康受试者中随机、开放、单次给药、两制剂、两周期、两序列、双交叉空腹和餐后状态下的生物等效性试验
100 项与 奥美沙坦酯氢氯噻嗪 相关的临床结果
登录后查看更多信息
100 项与 奥美沙坦酯氢氯噻嗪 相关的转化医学
登录后查看更多信息
100 项与 奥美沙坦酯氢氯噻嗪 相关的专利（医药）
登录后查看更多信息
9
项与 奥美沙坦酯氢氯噻嗪 相关的文献（医药）2014-12-26Current medicinal chemistry2区 · 医学
Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs
2区 · 医学
Review
作者: Kalgutkar, A S
Certain idiosyncratic adverse drug reactions (IADRs) can be triggered by electrophilic protein-reactive metabolites that are formed in the process of drug metabolism. While methodologies (e.g., structural alert concept in drug design, glutathione (GSH) trapping, and protein covalent binding) for examining reactive metabolite (RM) formation are available, predicting the IADR potential applying these parameters remains a significant challenge. The present work examines toxicity trends associated with the aniline structural alert in the top 200 prescribed drugs of 2011 and recently approved (2009-2013) small molecule drugs, in relation with 30 aniline-based drugs withdrawn from commercial use or associated with a black box warning for IADRs. The aniline sub-structure was found in several drugs from the toxic, most prescribed, and recently approved category. RMs resulting from the bioactivation of the aniline alert was also noted in the three categories chosen for comparison. A major discriminator between the toxic drugs and the majority of drugs in the most-prescribed list, however, was the daily dose--drugs most frequented associated with IADRs were the ones with higher daily doses (exceeding hundreds of milligrams). A greater tolerance for IADRs was also noted with certain drugs intended to treat rare, unmet medical needs (e.g., cancer). Overall, the analysis suggests that optimization of pharmacologic potency and pharmacokinetics that would lead to a lower daily dose, and therefore, a lower body burden of parent drug/metabolites, should be taken into consideration in drug discovery.
2014-10-01JOURNAL OF ANALYTICAL CHEMISTRY
Simultaneous determination and validation of some binary mixtures of antihypertensive drugs using ratio derivative spectrophotometric method
作者: Mehmet Gumustas ; Sibel A. Ozkan ; Sevinc Kurbanoglu
Ratio derivative spectrophotometric technique is presented for the rapid, accurate and precise simultaneous determination of olmesartan medoxomil (OLM), hydrochlorothiazide (HCT), and zofenopril (ZOF) as well as HCT binary mixtures in their dosage forms.First derivative of the ratio spectra (DD1) by measurements using different amplitudes was used and calibration graphs were established for 0.5-12 mg/mL HCT and 0.5-20 mg/mL OLM and ZOF.This method depends on first derivative of the ratio spectra by division of the absorption spectrum of the binary mixture by a standard spectrum of one of the components and then calculating the first derivative of the ratio spectrum.The first derivative of the ratio amplitudes at 250.4 and 291.5 nm for OLM, 250.4 and 298.1 nm for ZOF and 231.8, 332.2, 232.3 and 280.4 nm for HCT were selected for the determinationThe proposed methods were successfully applied for determining of both drug combinations (ZOF-HCT and OLM-HCT) in their synthetic mixtures and in pharmaceutical dosage forms.The described procedures are extensively validated, non-destructive and do not require any separation steps.
2013-07-01American journal of hypertension3区 · 医学
Dynamic View on Affordability of Fixed-Dose Combination Antihypertensive Drug Therapy
3区 · 医学
Article
作者: Wang, Junling ; Hong, Song Hee ; Tang, Jun
BACKGROUND:
The use of fixed-dose combinations (FDCs) has been increasing since the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommended using ≥2 drugs as the first-line drug therapy for patients with stage 2 hypertension. FDCs simplify the drug therapy regimen and reportedly lower the drug therapy cost compared with the free combination (FC) of 2 single-agent drugs. This study hypothesized that the affordability of FDCs over FCs would change over time depending on the availability of generic single-agent drugs.
METHODS:
This study used the 2009 Medical Expenditure Panel Survey. Antihypertensive drugs were identified based on the Food and Drug Administration national drug directory. Based on the 2 databases, regression models were run to predict average monthly drug cost as well as out-of-pocket cost for each prescription along with their 95% confidence intervals (CIs).
RESULTS:
Overall, FDCs (n = 26) had average monthly drug costs similar to respective FCs when FCs were not generically available. However, when FCs were generically available, FDCs (n = 11) had average drugs costs much higher than their respective FCs. For example, Lotrel as an FDC had an average monthly drug cost of $115.97 (95% CI = $96.59-$135.36), whereas its counterpart FC had an average monthly drug cost of $21.00 (95% CI = $18.23-$23.79).
CONCLUSIONS:
The cost advantage of FDCs over FCs was reversed when FCs were generically available. The finding of this study informs patients, health-care providers, and drug plans of the importance of making dynamic decisions on preferred drug therapy options depending on the availability of generic drugs.
100 项与 奥美沙坦酯氢氯噻嗪 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 2003-06-05 | |
| 原发性高血压 | 比利时 | 2003-03-30 | |
| 原发性高血压 | 法国 | 2003-03-30 | |
| 原发性高血压 | 德国 | 2003-03-30 | |
| 原发性高血压 | 希腊 | 2003-03-30 | |
| 原发性高血压 | 意大利 | 2003-03-30 | |
| 原发性高血压 | 卢森堡 | 2003-03-30 | |
| 原发性高血压 | 荷兰 | 2003-03-30 | |
| 原发性高血压 | 葡萄牙 | 2003-03-30 | |
| 原发性高血压 | 西班牙 | 2003-03-30 | |
| 原发性高血压 | 英国 | 2003-03-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 972 | OM+HCTZ (OM/HCTZ 40/25mg + 20/12.5 Matching Placebo) | 網範鑰齋網簾蓋築鏇廠(製襯襯簾繭積鬱糧觸獵) = 鑰醖鬱顧襯顧遞觸獵窪 糧廠構繭衊顧簾鑰壓簾 (壓築構衊衊構鬱鬱鑰憲, 8.796) 更多 | - | 2009-06-17 | ||
OM+HCTZ (OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo) | 網範鑰齋網簾蓋築鏇廠(製襯襯簾繭積鬱糧觸獵) = 範襯選鹽壓窪鬱膚艱簾 糧廠構繭衊顧簾鑰壓簾 (壓築構衊衊構鬱鬱鑰憲, 8.622) 更多 | ||||||
临床3期 | 1,011 | OM+HCTZ (OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo) | 憲鬱廠廠艱鹹餘鏇簾積(獵遞築廠窪鬱範構顧鏇) = 網選鹽遞觸選襯窪糧選 衊艱鹹壓壓餘簾範鹽鑰 (鬱醖壓顧製壓簾顧鬱願, 8.851) 更多 | - | 2009-04-20 | ||
OM+HCTZ (OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo) | 憲鬱廠廠艱鹹餘鏇簾積(獵遞築廠窪鬱範構顧鏇) = 膚醖窪構憲觸壓製淵廠 衊艱鹹壓壓餘簾範鹽鑰 (鬱醖壓顧製壓簾顧鬱願, 7.928) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用